ATE125701T1 - Gabapentin und dessen derivate zur behandlung neurodegenerativer krankheiten. - Google Patents
Gabapentin und dessen derivate zur behandlung neurodegenerativer krankheiten.Info
- Publication number
- ATE125701T1 ATE125701T1 AT91100109T AT91100109T ATE125701T1 AT E125701 T1 ATE125701 T1 AT E125701T1 AT 91100109 T AT91100109 T AT 91100109T AT 91100109 T AT91100109 T AT 91100109T AT E125701 T1 ATE125701 T1 AT E125701T1
- Authority
- AT
- Austria
- Prior art keywords
- gabapentin
- derivatives
- treatment
- neurodegenerative diseases
- huntington
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45991290A | 1990-01-02 | 1990-01-02 | |
US07/615,151 US5084479A (en) | 1990-01-02 | 1990-11-23 | Novel methods for treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE125701T1 true ATE125701T1 (de) | 1995-08-15 |
Family
ID=27039510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91100109T ATE125701T1 (de) | 1990-01-02 | 1991-01-02 | Gabapentin und dessen derivate zur behandlung neurodegenerativer krankheiten. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5084479A (de) |
EP (1) | EP0446570B1 (de) |
JP (1) | JP2903434B2 (de) |
AT (1) | ATE125701T1 (de) |
DE (1) | DE69111642T2 (de) |
DK (1) | DK0446570T3 (de) |
HK (1) | HK1005166A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025035A (en) * | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
US5217957A (en) * | 1991-08-20 | 1993-06-08 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
NZ331143A (en) * | 1996-03-14 | 2001-06-29 | Warner Lambert Co | Substituted cyclic amino acids as pharmaceutical agents |
US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
CA2292558C (en) * | 1997-06-30 | 2006-09-19 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane nmda receptor antagonists |
US6194459B1 (en) | 1997-08-19 | 2001-02-27 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants |
AU9318398A (en) | 1997-10-07 | 1999-04-27 | Warner-Lambert Company | Process for preparing a cyclic amino acid anticonvulsant compound |
PL199794B1 (pl) | 1997-10-27 | 2008-10-31 | Warner Lambert Co | Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów |
US6984659B2 (en) | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
DE19751062A1 (de) * | 1997-11-18 | 1999-07-08 | Univ Ludwigs Albert | An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels |
PL204921B1 (pl) | 1998-05-15 | 2010-02-26 | Warner Lambert Co | Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania |
WO1999059572A1 (en) * | 1998-05-15 | 1999-11-25 | Warner-Lambert Company | Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same |
US6294198B1 (en) | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
US6350768B1 (en) | 1999-11-24 | 2002-02-26 | Aventis Pharma S.A. | Combination of riluzole and of gabapentin and its use as a medicament |
FR2801217B1 (fr) * | 1999-11-24 | 2002-12-06 | Aventis Pharma Sa | Association de riluzole et de gabapentine et son utilisation comme medicament |
PL363155A1 (en) * | 2000-06-16 | 2004-11-15 | Teva Pharmaceutical Industries, Ltd. | Stable gabapentin having ph within a controlled range |
WO2001097612A1 (en) | 2000-06-16 | 2001-12-27 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 2o ppm of chlorine ion |
WO2002000209A2 (en) * | 2000-06-26 | 2002-01-03 | Warner-Lambert Company | Gabapentin analogues for sleep disorders |
US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
MXPA03011566A (es) * | 2001-06-11 | 2004-10-28 | Xenoport Inc | Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida. |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20030119908A1 (en) * | 2001-12-21 | 2003-06-26 | Zambon Group S.P.A. | Stable gabapentin compositions |
ITMI20012750A1 (it) | 2001-12-21 | 2003-06-21 | Procos Spa | Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura |
CA2473536A1 (en) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
WO2003089403A1 (en) * | 2002-04-16 | 2003-10-30 | Taro Pharmaceutical Industries Ltd. | Process for preparing gabapentin |
AU2003243180A1 (en) * | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
WO2004052360A1 (en) | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
WO2005000294A1 (en) * | 2003-06-06 | 2005-01-06 | Pharmacia Corporation | Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
BRPI0414481A (pt) | 2003-09-17 | 2006-11-14 | Xenoport Inc | métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica |
CA2541752C (en) | 2003-10-14 | 2012-01-03 | Xenoport, Inc. | Crystalline form of gamma-aminobutyric acid analog |
WO2005082372A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
US20050187295A1 (en) * | 2004-02-19 | 2005-08-25 | Surendra Kalyan | Processes for the preparation of gabapentin |
ITMI20040579A1 (it) * | 2004-03-25 | 2004-06-25 | Zambon Spa | Processo di preparazione di gabapentina |
NZ554737A (en) * | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
WO2011151708A1 (en) | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
EP2923694B1 (de) | 2014-03-27 | 2018-11-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orale flüssige pharmazeutische lösung von gabapentin |
AU2020370758A1 (en) * | 2019-10-25 | 2022-06-02 | Kyoto University | Preventative or therapeutic agent for tauopathy |
CN115350172A (zh) * | 2022-08-12 | 2022-11-18 | 昆明医科大学 | Gabapentin对AD情景记忆改善的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
-
1990
- 1990-11-23 US US07/615,151 patent/US5084479A/en not_active Expired - Lifetime
- 1990-12-27 JP JP2418309A patent/JP2903434B2/ja not_active Expired - Fee Related
-
1991
- 1991-01-02 DK DK91100109.7T patent/DK0446570T3/da active
- 1991-01-02 EP EP91100109A patent/EP0446570B1/de not_active Expired - Lifetime
- 1991-01-02 AT AT91100109T patent/ATE125701T1/de not_active IP Right Cessation
- 1991-01-02 DE DE69111642T patent/DE69111642T2/de not_active Expired - Fee Related
-
1998
- 1998-05-15 HK HK98104232A patent/HK1005166A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69111642T2 (de) | 1996-01-25 |
HK1005166A1 (en) | 1998-12-24 |
EP0446570A3 (en) | 1992-04-01 |
JP2903434B2 (ja) | 1999-06-07 |
EP0446570B1 (de) | 1995-08-02 |
DK0446570T3 (da) | 1995-11-27 |
EP0446570A2 (de) | 1991-09-18 |
JPH04210915A (ja) | 1992-08-03 |
US5084479A (en) | 1992-01-28 |
DE69111642D1 (de) | 1995-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69111642T2 (de) | Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. | |
DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
UY26813A1 (es) | Compuestos para tratar enfermedad de alzheimer | |
ATE302751T1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
ATE478669T1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
ATE343388T1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
TW229156B (de) | ||
DE69716810D1 (de) | 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one | |
ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
NZ234672A (en) | N-(1,2,3,4-tetrahydro-9-acridinyl)amide and carbamate derivatives and pharmaceutical compositions | |
ATE526981T1 (de) | Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen | |
ATE268337T1 (de) | C11-carbamate von antibakteriellen makroliden | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
DE3854121T2 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
DE69911689D1 (de) | Verfahren zur Herstellung von S-Aryl-L-cystein und Derivate | |
DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
DE69916577D1 (de) | Azetidincarboxamid-derivate zur behandlung von zns störungen | |
DE69930880D1 (de) | Bicyclische(3.1.0)hexane und verwandte Verbindungen | |
HUT56559A (en) | Process for producing ascorbinic acid derivatives and pharma | |
DE69026991T2 (de) | Phospholipide zur Behandlung der multiplen Sklerose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |